Skip to main content
. Author manuscript; available in PMC: 2012 Apr 7.
Published in final edited form as: J Acquir Immune Defic Syndr. 2010 Dec 15;55(5):558–564. doi: 10.1097/QAI.0b013e3181ee3d82

FIGURE 4.

FIGURE 4

Incidence of A, total malignancies at week 48 and at end of blinded therapy, and B, exposure-adjusted malignancies by type at end of blinded therapy. *Includes anal cancer stage 0; **T-cell, B-cell and diffuse large B-cell lymphoma; †Includes testicular and tongue neoplasms; §Includes bone, liver and peritoneum; ‡Includes squamous cell carcinoma of the skin.